IM-250

IM-250 is an anti-herpetic drug candidate developed by Innovative Molecules Gmbh. The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.
Innovative Molecules raised 20 million euro for clinical trials on humans.